293b cpd has been researched along with glucagon-like peptide 1 in 1 studies
| Studies (293b cpd) | Trials (293b cpd) | Recent Studies (post-2010) (293b cpd) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 100 | 0 | 16 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | 293b cpd (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L; Lu, H; Ren, X; Wang, F; Zou, J | 1 |
1 other study(ies) available for 293b cpd and glucagon-like peptide 1
| Article | Year |
|---|---|
Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice.
Topics: Animals; Chromans; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; In Vitro Techniques; Insulin; Insulin Resistance; Insulin Secretion; Intestines; Islets of Langerhans; KCNQ1 Potassium Channel; Mice; Pancreas; Sulfonamides | 2014 |